Regulation of the dopamine and vesicular monoamine transporters: Pharmacological targets and implications for disease

Pharmacological Reviews

Volumn 67, Issue 4, 2015, Pages 1005-1024

  German, Christopher L ^a   Baladi, Michelle G ^a   McFadden, Lisa M ^a   Hanson, Glen R ^a   Fleckenstein, Annette E ^a  

^a UNIVERSITY OF UTAH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOPAMINE; DOPAMINE RECEPTOR STIMULATING AGENT; DOPAMINE TRANSPORTER; DOPAMINE UPTAKE INHIBITOR; ESTROGEN; HYPOPHYSIS ADENYLATE CYCLASE ACTIVATING POLYPEPTIDE; INSULIN; LOBELINE; METHAMPHETAMINE; METHYLPHENIDATE; RESERPINE; TETRABENAZINE; VESICULAR MONOAMINE TRANSPORTER; VESICULAR MONOAMINE TRANSPORTER 2; ADRENERGIC RECEPTOR AFFECTING AGENT;

ATTENTION DEFICIT DISORDER; CELLULAR DISTRIBUTION; DOPAMINERGIC SYSTEM; DRUG EFFICACY; DRUG TARGETING; HUMAN; NERVE ENDING; NEUROBIOLOGY; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN PROCESSING; PROTEIN PROTEIN INTERACTION; REGULATORY MECHANISM; REVIEW; SIGNAL TRANSDUCTION; SUBSTANCE ABUSE; SYNAPSE VESICLE; ANIMAL; CENTRAL NERVOUS SYSTEM DISEASE; CLASSIFICATION; GLYCOSYLATION; METABOLISM; PATHOPHYSIOLOGY; PHOSPHORYLATION; PHYSIOLOGY; SYNAPTIC TRANSMISSION;

ADRENERGIC UPTAKE INHIBITORS; ANIMALS; CENTRAL NERVOUS SYSTEM DISEASES; DOPAMINE; DOPAMINE AGENTS; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; GLYCOSYLATION; HUMANS; PHOSPHORYLATION; SIGNAL TRANSDUCTION; SYNAPTIC TRANSMISSION; VESICULAR MONOAMINE TRANSPORT PROTEINS;

EID: 84942433275     PISSN: 00316997     EISSN: 15210081     Source Type: Journal    
DOI: 10.1124/pr.114.010397     Document Type: Review

References (284)

1. Adkins EM, Samuvel DJ, Fog JU, Eriksen J, Jayanthi LD, Vaegter CB, Ramamoorthy S, and Gether U (2007) Membrane mobility and microdomain association of the dopamine transporter studied with fluorescence correlation spectroscopy and fluorescence recovery after photobleaching. Biochemistry 46:10484-10497.
2. Afonso-Oramas D, Cruz-Muros I, Alvarezdela Rosa D, Abreu P, Giráldez T, Castro-Hernández J, Salas-Hernández J, Lanciego JL, Rodríguez M, and González-Hernández T (2009) Dopamine transporter glycosylation correlates with the vulnerability of midbrain dopaminergic cells in Parkinson’s disease. Neurobiol Dis 36:494-508.
3. Alter SP, Lenzi GM, Bernstein AI, and Miller GW (2013) Vesicular integrity in Parkinson’s disease. Curr Neurol Neurosci Rep 13:362.
4. Anker JJ and Carroll ME (2011) Females are more vulnerable to drug abuse than males: evidence from preclinical studies and the role of ovarian hormones. Curr Top Behav Neurosci 8:73-96.
5. Assmann BE, Robinson RO, Surtees RA, Bräutigam C, Heales SJ, Wevers RA, Zschocke J, Hyland K, Sharma R, and Hoffmann GF (2004) Infantile Parkinsonism-dystonia and elevated dopamine metabolites in CSF. Neurology 62: 1872-1874.
6. Baladi MG, Daws LC, and France CP (2012) You are what you eat: influence of type and amount of food consumed on central dopamine systems and the behavioral effects of direct- and indirect-acting dopamine receptor agonists. Neuropharmacology 63:76-86.
7. Baladi MG, Horton RE, Owens WA, Daws LC, and France CP (2015) Eating high fat chow decreases dopamine clearance in adolescent and adult male rats but selectively enhances the locomotor stimulating effects of cocaine in adolescents. Int J Neuropsychopharmacol 18:24.
8. Barrett AC, Miller JR, Dohrmann JM, and Caine SB (2004) Effects of dopamine indirect agonists and selective D1-like and D2-like agonists and antagonists on cocaine self-administration and food maintained responding in rats. Neuropharmacology 47 (Suppl 1):256-273.
9. Baucum AJ 2nd, Rau KS, Riddle EL, Hanson GR, and Fleckenstein AE (2004) Methamphetamine increases dopamine transporter higher molecular weight complex formation via a dopamine- and hyperthermia-associated mechanism. J Neurosci 24:3436-3443.
10. Berman SB, Zigmond MJ, and Hastings TG (1996) Modification of dopamine transporter function: effect of reactive oxygen species and dopamine. J Neurochem 67: 593-600.
11. Bernstein AI, Stout KA, and Miller GW (2014) The vesicular monoamine transporter 2: an underexplored pharmacological target. Neurochem Int 73:89-97.
12. Beuming T, Kniazeff J, Bergmann ML, Shi L, Gracia L, Raniszewska K, Newman AH, Javitch JA, Weinstein H, and Gether U, et al. (2008) The binding sites for cocaine and dopamine in the dopamine transporter overlap. Nat Neurosci 11: 780-789.
13. Bjerggaard C, Fog JU, Hastrup H, Madsen K, Loland CJ, Javitch JA, and Gether U (2004) Surface targeting of the dopamine transporter involves discrete epitopes in the distal C terminus but does not require canonical PDZ domain interactions. J Neurosci 24:7024-7036.
14. Bobb AJ, Addington AM, Sidransky E, Gornick MC, Lerch JP, Greenstein DK, Clasen LS, Sharp WS, Inoff-Germain G, and Wavrant-De Vrièze F, et al. (2005) Support for association between ADHD and two candidate genes: NET1 and DRD1. Am J Med Genet B Neuropsychiatr Genet 134B:67-72.
15. Bohnen NI, Albin RL, Koeppe RA, Wernette KA, Kilbourn MR, Minoshima S, and Frey KA (2006) Positron emission tomography of monoaminergic vesicular binding in aging and Parkinson disease. J Cereb Blood Flow Metab 26:1198-1212.
16. Boileau I, Rusjan P, Houle S, Wilkins D, Tong J, Selby P, Guttman M, Saint-Cyr JA, Wilson AA, and Kish SJ (2008) Increased vesicular monoamine transporter binding during early abstinence in human methamphetamine users: Is VMAT2 a stable dopamine neuron biomarker? J Neurosci 28:9850-9856.
17. Bossé R, Rivest R, and Di Paolo T (1997) Ovariectomy and estradiol treatment affect the dopamine transporter and its gene expression in the rat brain. Brain Res Mol Brain Res 46:343-346.
18. Boudanova E, Navaroli DM, Stevens Z, and Melikian HE (2008) Dopamine transporter endocytic determinants: carboxy terminal residues critical for basal and PKC-stimulated internalization. Mol Cell Neurosci 39:211-217.
19. Bowton E, Saunders C, Reddy IA, Campbell NG, Hamilton PJ, Henry LK, Coon H, Sakrikar D, Veenstra-VanderWeele JM, and Blakely RD, et al. (2014) SLC6A3 coding variant Ala559Val found in two autism probands alters dopamine transporter function and trafficking. Transl Psychiatry 4:e464.
20. Braak H, Del Tredici K, Rüb U, de Vos RA, Jansen Steur EN, and Braak E (2003) Staging of brain pathology related to sporadic Parkinson’s disease. Neurobiol Aging 24:197-211.
21. Brown JM, Hanson GR, and Fleckenstein AE (2000) Methamphetamine rapidly decreases vesicular dopamine uptake. J Neurochem 74:2221-2223.
22. Brown JM, Hanson GR, and Fleckenstein AE (2001a) Cocaine-induced increases in vesicular dopamine uptake: role of dopamine receptors. J Pharmacol Exp Ther 298: 1150-1153.
23. Brown JM, Hanson GR, and Fleckenstein AE (2001b) Regulation of the vesicular monoamine transporter-2: a novel mechanism for cocaine and other psychostimulants. J Pharmacol Exp Ther 296:762-767.
24. Brown JM, Riddle EL, Sandoval V, Weston RK, Hanson JE, Crosby MJ, Ugarte YV, Gibb JW, Hanson GR, and Fleckenstein AE (2002) A single methamphetamine administration rapidly decreases vesicular dopamine uptake. J Pharmacol Exp Ther 302:497-501.
25. Callaghan RC, Cunningham JK, Sykes J, and Kish SJ (2012) Increased risk of Parkinson’s disease in individuals hospitalized with conditions related to the use of methamphetamine or other amphetamine-type drugs. Drug Alcohol Depend 120: 35-40.
26. Cameron DL and Williams JT (1993) Dopamine D1 receptors facilitate transmitter release. Nature 366:344-347.
27. Carroll FI, Blough BE, Abraham P, Mills AC, Holleman JA, Wolckenhauer SA, Decker AM, Landavazo A, McElroy KT, and Navarro HA, et al. (2009) Synthesis and biological evaluation of bupropion analogues as potential pharmacotherapies for cocaine addiction. J Med Chem 52:6768-6781.
28. Carroll FI, Howard JL, Howell LL, Fox BS, and Kuhar MJ (2006) Development of the dopamine transporter selective RTI-336 as a pharmacotherapy for cocaine abuse. AAPS J 8:E196-E203.
29. Cartier EA, Parra LA, Baust TB, Quiroz M, Salazar G, Faundez V, Egaña L, and Torres GE (2010) A biochemical and functional protein complex involving dopamine synthesis and transport into synaptic vesicles. J Biol Chem 285: 1957-1966.
30. Carvelli L, Morón JA, Kahlig KM, Ferrer JV, Sen N, Lechleiter JD, Leeb-Lundberg LM, Merrill G, Lafer EM, and Ballou LM, et al. (2002) PI 3-kinase regulation of dopamine uptake. J Neurochem 81:859-869.
31. Cervinski MA, Foster JD, and Vaughan RA (2005). Psychoactive substrates stimulate dopamine transporter phosphorylation and down-regulation by cocaine-sensitive and protein kinase C-dependent mechanisms. J Biol Chem 280:40442-40449.
32. Chang L, Alicata D, Ernst T, and Volkow N (2007) Structural and metabolic brain changes in the striatum associated with methamphetamine abuse. Addiction 102 (Suppl 1):16-32.
33. Chang MY, Lee SH, Kim JH, Lee KH, Kim YS, Son H, and Lee YS (2001) Protein kinase C-mediated functional regulation of dopamine transporter is not achieved by direct phosphorylation of the dopamine transporter protein. J Neurochem 77: 754-761.
34. Chavez C, Hollaus M, Scarr E, Pavey G, Gogos A, and van den Buuse M (2010) The effect of estrogen on dopamine and serotonin receptor and transporter levels in the brain: an autoradiography study. Brain Res 1321:51-59.
35. Cho NH, Chan JC, Jang HC, Lim S, Kim HL, and Choi SH (2009) Cigarette smoking is an independent risk factor for type 2 diabetes: a four-year community-based prospective study. Clin Endocrinol (Oxf) 71:679-685.
36. Chu PW, Hadlock GC, Vieira-Brock P, Stout K, Hanson GR, and Fleckenstein AE (2010) Methamphetamine alters vesicular monoamine transporter-2 function and potassium-stimulated dopamine release. J Neurochem 115:325-332.
37. Colburn RW, Goodwin FK, Murphy DL, Bunney WE Jr, and Davis JM (1968) Quantitative studies of norepinephrine uptake by synaptosomes. Biochem Pharmacol 17:957-964.
38. Copeland BJ, Vogelsberg V, Neff NH, and Hadjiconstantinou M (1996) Protein kinase C activators decrease dopamine uptake into striatal synaptosomes. J Pharmacol Exp Ther 277:1527-1532.
39. Covey DP, Juliano SA, and Garris PA (2013) Amphetamine elicits opposing actions on readily releasable and reserve pools for dopamine. PLoS One 8:e60763.
40. Cragg SJ and Rice ME (2004) DAncing past the DAT at a DA synapse. Trends Neurosci 27:270-277.
41. Cremona ML, Matthies HJ, Pau K, Bowton E, Speed N, Lute BJ, Anderson M, Sen N, Robertson SD, and Vaughan RA, et al. (2011) Flotillin-1 is essential for PKCtriggered endocytosis and membrane microdomain localization of DAT. Nat Neurosci 14:469-477.
42. Crits-Christoph P, Newberg A, Wintering N, Ploessl K, Gibbons MB, Ring-Kurtz S, Gallop R, and Present J (2008) Dopamine transporter levels in cocaine dependent subjects. Drug Alcohol Depend 98:70-76.
43. Curtin K, Fleckenstein AE, Robison RJ, Crookston MJ, Smith KR, and Hanson GR (2015) Methamphetamine/amphetamine abuse and risk of Parkinson’s disease in Utah: a population-based assessment. Drug Alcohol Depend 146:30-38.
44. Daniels GM and Amara SG (1999) Regulated trafficking of the human dopamine transporter. Clathrin-mediated internalization and lysosomal degradation in response to phorbol esters. J Biol Chem 274:35794-35801.
45. Daws LC, Avison MJ, Robertson SD, Niswender KD, Galli A, and Saunders C (2011) Insulin signaling and addiction. Neuropharmacology 61:1123-1128.
46. Daws LC, Callaghan PD, Morón JA, Kahlig KM, Shippenberg TS, Javitch JA, and Galli A (2002) Cocaine increases dopamine uptake and cell surface expression of dopamine transporters. Biochem Biophys Res Commun 290:1545-1550.
47. dela Fuente-Fernández R, Schulzer M, Kuramoto L, Cragg J, Ramachandiran N, Au WL, Mak E, McKenzie J, McCormick S, and Sossi V, et al. (2011) Age-specific progression of nigrostriatal dysfunction in Parkinson’s disease. Ann Neurol 69:803-810.
48. Dengler HJ, Spiegel HE, and Titus EO (1961) Uptake of tritium-labeled norepinephrine in brain and other tissues of cat in vitro. Science 133:1072-1073.
49. Desai RI, Kopajtic TA, French D, Newman AH, and Katz JL (2005a) Relationship between in vivo occupancy at the dopamine transporter and behavioral effects of cocaine, GBR 12909 [1-2-[bis-(4-fluorophenyl)methoxy]ethyl-4-(3-phenylpropyl)piperazine], and benztropine analogs. J Pharmacol Exp Ther 315:397-404.
50. Desai RI, Kopajtic TA, Koffarnus M, Newman AH, and Katz JL (2005b) Identification of a dopamine transporter ligand that blocks the stimulant effects of cocaine. J Neurosci 25:1889-1893.
51. Disshon KA, Boja JW, and Dluzen DE (1998) Inhibition of striatal dopamine transporter activity by 17beta-estradiol. Eur J Pharmacol 345:207-211.
52. Dixon L, Weiden P, Delahanty J, Goldberg R, Postrado L, Lucksted A, and Lehman A (2000) Prevalence and correlates of diabetes in national schizophrenia samples. Schizophr Bull 26:903-912.
53. Dougherty DD, Bonab AA, Spencer TJ, Rauch SL, Madras BK, and Fischman AJ (1999) Dopamine transporter density in patients with attention deficit hyperactivity disorder. Lancet 354:2132-2133.
54. Dutta AK, Zhang S, Kolhatkar R, and Reith ME (2003) Dopamine transporter as target for drug development of cocaine dependence medications. Eur J Pharmacol 479:93-106.
55. Egaña LA, Cuevas RA, Baust TB, Parra LA, Leak RK, Hochendoner S, Peña K, Quiroz M, Hong WC, and Dorostkar MM, et al. (2009) Physical and functional interaction between the dopamine transporter and the synaptic vesicle protein synaptogyrin-3. J Neurosci 29:4592-4604.
56. Erickson JD, Eiden LE, and Hoffman BJ (1992) Expression cloning of a reserpine-sensitive vesicular monoamine transporter. Proc Natl Acad Sci USA 89:10993-10997.
57. Erickson JD, Schafer MK, Bonner TI, Eiden LE, and Weihe E (1996) Distinct pharmacological properties and distribution in neurons and endocrine cells of two isoforms of the human vesicular monoamine transporter. Proc Natl Acad Sci USA 93:5166-5171.
58. Eriksen J, Bjørn-Yoshimoto WE, Jørgensen TN, Newman AH, and Gether U (2010a) Postendocytic sorting of constitutively internalized dopamine transporter in cell lines and dopaminergic neurons. J Biol Chem 285:27289-27301.
59. Eriksen J, Jørgensen TN, and Gether U (2010b) Regulation of dopamine transporter function by protein-protein interactions: new discoveries and methodological challenges. J Neurochem 113:27-41.
60. Eriksen J, Rasmussen SG, Rasmussen TN, Vaegter CB, Cha JH, Zou MF, Newman AH, and Gether U (2009) Visualization of dopamine transporter trafficking in live neurons by use of fluorescent cocaine analogs. J Neurosci 29:6794-6808.
61. Eyerman DJ and Yamamoto BK (2005) Lobeline attenuates methamphetamineinduced changes in vesicular monoamine transporter 2 immunoreactivity and monoamine depletions in the striatum. J Pharmacol Exp Ther 312:160-169.
62. Eyerman DJ and Yamamoto BK (2007) A rapid oxidation and persistent decrease in the vesicular monoamine transporter 2 after methamphetamine. J Neurochem 103:1219-1227.
63. Facchini FS, Hollenbeck CB, Jeppesen J, Chen YD, and Reaven GM (1992) Insulin resistance and cigarette smoking. Lancet 339:1128-1130.
64. Faith MS, Matz PE, and Jorge MA (2002) Obesity-depression associations in the population. J Psychosom Res 53:935-942.
65. Fearnley JM and Lees AJ (1991) Ageing and Parkinson’s disease: substantia nigra regional selectivity. Brain 114:2283-2301.
66. Fei H, Grygoruk A, Brooks ES, Chen A, and Krantz DE (2008) Trafficking of vesicular neurotransmitter transporters. Traffic 9:1425-1436.
67. Figlewicz DP (2003) Insulin, food intake, and reward. Semin Clin Neuropsychiatry 8: 82-93.
68. Figlewicz DP, Evans SB, Murphy J, Hoen M, and Baskin DG (2003) Expression of receptors for insulin and leptin in the ventral tegmental area/substantia nigra (VTA/SN) of the rat. Brain Res 964:107-115.
69. Figlewicz DP, Szot P, Chavez M, Woods SC, and Veith RC (1994) Intraventricular insulin increases dopamine transporter mRNA in rat VTA/substantia nigra. Brain Res 644:331-334.
70. Fiorino DF, Coury A, Fibiger HC, and Phillips AG (1993) Electrical stimulation of reward sites in the ventral tegmental area increases dopamine transmission in the nucleus accumbens of the rat. Behav Brain Res 55:131-141.
71. Fleckenstein AE, Gibb JW, and Hanson GR (2000) Differential effects of stimulants on monoaminergic transporters: pharmacological consequences and implications for neurotoxicity. Eur J Pharmacol 406:1-13.
72. Fleckenstein AE, Haughey HM, Metzger RR, Kokoshka JM, Riddle EL, Hanson JE, Gibb JW and Hanson GR (1999) Differential effects of psychostimulants and related agents on dopaminergic and serotonergic transporter function. Eur J Pharmacol 382:45-49.
73. Fleckenstein AE, Metzger RR, Beyeler ML, Gibb JW, and Hanson GR (1997a) Oxygen radicals diminish dopamine transporter function in rat striatum. Eur J Pharmacol 334:111-114.
74. Fleckenstein AE, Metzger RR, Wilkins DG, Gibb JW, and Hanson GR (1997b) Rapid and reversible effects of methamphetamine on dopamine transporters. J Pharmacol Exp Ther 282:834-838.
75. Fleckenstein AE, Volz TJ, Riddle EL, Gibb JW, and Hanson GR (2007) New insights into the mechanism of action of amphetamines. Annu Rev Pharmacol Toxicol 47:681-698.
76. Floor E and Meng L (1996) Amphetamine releases dopamine from synaptic vesicles by dual mechanisms. Neurosci Lett 215:53-56.
77. Fog JU, Khoshbouei H, Holy M, Owens WA, Vaegter CB, Sen N, Nikandrova Y, Bowton E, McMahon DG, and Colbran RJ, et al. (2006) Calmodulin kinase II interacts with the dopamine transporter C terminus to regulate amphetamineinduced reverse transport. Neuron 51:417-429.
78. Foster JD, Adkins SD, Lever JR, and Vaughan RA (2008) Phorbol ester induced trafficking-independent regulation and enhanced phosphorylation of the dopamine transporter associated with membrane rafts and cholesterol. J Neurochem 105: 1683-1699.
79. Foster JD, Pananusorn B, and Vaughan RA (2002) Dopamine transporters are phosphorylated on N-terminal serines in rat striatum. J Biol Chem 277: 25178-25186.
80. Foster JD and Vaughan RA (2011) Palmitoylation controls dopamine transporter kinetics, degradation, and protein kinase C-dependent regulation. J Biol Chem 286:5175-5186.
81. Foster JD, Yang JW, Moritz AE, Challasivakanaka S, Smith MA, Holy M, Wilebski K, Sitte HH, and Vaughan RA (2012) Dopamine transporter phosphorylation site threonine 53 regulates substrate reuptake and amphetamine-stimulated efflux. J Biol Chem 287:29702-29712.
82. Fountaine TM and Wade-Martins R (2007) RNA interference-mediated knockdown of alpha-synuclein protects human dopaminergic neuroblastoma cells from MPP(+) toxicity and reduces dopamine transport. J Neurosci Res 85:351-363.
83. Frank S and Jankovic J (2010) Advances in the pharmacological management of Huntington’s disease. Drugs 70:561-571.
84. Franko DL, Dorer DJ, Keel PK, Jackson S, Manzo MP, and Herzog DB (2008) Interactions between eating disorders and drug abuse. J Nerv Ment Dis 196:556-561.
85. Frey KA, Koeppe RA, and Kilbourn MR (2001) Imaging the vesicular monoamine transporter. Adv Neurol 86:237-247.
86. Furman CA, Chen R, Guptaroy B, Zhang M, Holz RW, and Gnegy M (2009) Dopamine and amphetamine rapidly increase dopamine transporter trafficking to the surface: live-cell imaging using total internal reflection fluorescence microscopy. J Neurosci 29:3328-3336.
87. Galloway GP, Buscemi R, Coyle JR, Flower K, Siegrist JD, Fiske LA, Baggott MJ, Li L, Polcin D, and Chen CY, et al. (2011) A randomized, placebo-controlled trial of sustained-release dextroamphetamine for treatment of methamphetamine addiction. Clin Pharmacol Ther 89:276-282.
88. German CL, Hanson GR, and Fleckenstein AE (2012) Amphetamine and methamphetamine reduce striatal dopamine transporter function without concurrent dopamine transporter relocalization. J Neurochem 123:288-297.
89. Gill M, Daly G, Heron S, Hawi Z, and Fitzgerald M (1997) Confirmation of association between attention deficit hyperactivity disorder and a dopamine transporter polymorphism. Mol Psychiatry 2:311-313.
90. Gillies GE and McArthur S (2010) Estrogen actions in the brain and the basis for differential action in men and women: a case for sex-specific medicines. Pharmacol Rev 62:155-198.
91. Giovanni A, Liang LP, Hastings TG, and Zigmond MJ (1995) Estimating hydroxyl radical content in rat brain using systemic and intraventricular salicylate: impact of methamphetamine. J Neurochem 64:1819-1825.
92. Giros B, el Mestikawy S, Bertrand L, and Caron MG (1991) Cloning and functional characterization of a cocaine-sensitive dopamine transporter. FEBS Lett 295: 149-154.
93. Giros B, el Mestikawy S, Godinot N, Zheng K, Han H, Yang-Feng T, and Caron MG (1992) Cloning, pharmacological characterization, and chromosome assignment of the human dopamine transporter. Mol Pharmacol 42:383-390.
94. Giros B, Jaber M, Jones SR, Wightman RM, and Caron MG (1996) Hyperlocomotion and indifference to cocaine and amphetamine in mice lacking the dopamine transporter. Nature 379:606-612.
95. Glowinski J, Kopin IJ, and Axelrod J (1965) Metabolism of (H3)Norepinephrine in the Rat Brain. J Neurochem 12:25-30.
96. Gorentla BK, Moritz AE, Foster JD, and Vaughan RA (2009) Proline-directed phosphorylation of the dopamine transporter N-terminal domain. Biochemistry 48: 1067-1076.
97. Grabowski J, Rhoades H, Schmitz J, Stotts A, Daruzska LA, Creson D, and Moeller FG (2001) Dextroamphetamine for cocaine-dependence treatment: a double-blind randomized clinical trial. J Clin Psychopharmacol 21:522-526.
98. Grabowski J, Roache JD, Schmitz JM, Rhoades H, Creson D, and Korszun A (1997) Replacement medication for cocaine dependence: methylphenidate. J Clin Psychopharmacol 17:485-488.
99. Granas C, Ferrer J, Loland CJ, Javitch JA, and Gether U (2003) N-terminal truncation of the dopamine transporter abolishes phorbol ester- and substance P receptorstimulated phosphorylation without impairing transporter internalization. J Biol Chem 278:4990-5000.
100. Grünhage F, Schulze TG, Müller DJ, Lanczik M, Franzek E, Albus M, Borrmann-Hassenbach M, Knapp M, Cichon S, and Maier W, et al. (2000) Systematic screening for DNA sequence variation in the coding region of the human dopamine transporter gene (DAT1). Mol Psychiatry 5:275-282.
101. Guillot TS, Richardson JR, Wang MZ, Li YJ, Taylor TN, Ciliax BJ, Zachrisson O, Mercer A, and Miller GW (2008) PACAP38 increases vesicular monoamine transporter 2 (VMAT2) expression and attenuates methamphetamine toxicity. Neuropeptides 42:423-434.
102. Hadlock GC, Chu PW, Walters ET, Hanson GR, and Fleckenstein AE (2010) Methamphetamine-induced dopamine transporter complex formation and dopaminergic deficits: the role of D2 receptor activation. J Pharmacol Exp Ther 335: 207-212.
103. Halliday GM and McCann H (2010) The progression of pathology in Parkinson’s disease. Ann N Y Acad Sci 1184:188-195.
104. Hamilton PJ, Belovich AN, Khelashvili G, Saunders C, Erreger K, Javitch JA, Sitte HH, Weinstein H, Matthies HJ, and Galli A (2014) PIP2 regulates psychostimulant behaviors through its interaction with a membrane protein. Nat Chem Biol 10: 582-589.
105. Hannah MJ, Schmidt AA, and Huttner WB (1999) Synaptic vesicle biogenesis. Annu Rev Cell Dev Biol 15:733-798.
106. Hansen FH, Skjørringe T, Yasmeen S, Arends NV, Sahai MA, Erreger K, Andreassen TF, Holy M, Hamilton PJ, and Neergheen V, et al. (2014) Missense dopamine transporter mutations associate with adult parkinsonism and ADHD. J Clin Invest 124:3107-3120.
107. Hanson GR, Hoonakker AJ, Robson CM, McFadden LM, Frankel PS, and Alburges ME (2013) Response of neurotensin basal ganglia systems during extinction of methamphetamine self-administration in rat. J Pharmacol Exp Ther 346:173-181.
108. Harrod SB, Dwoskin LP, Crooks PA, Klebaur JE, and Bardo MT (2001) Lobeline attenuates d-methamphetamine self-administration in rats. J Pharmacol Exp Ther 298:172-179.
109. Hart H, Radua J, Nakao T, Mataix-Cols D, and Rubia K (2013) Meta-analysis of functional magnetic resonance imaging studies of inhibition and attention in attention-deficit/hyperactivity disorder: exploring task-specific, stimulant medication, and age effects. JAMA Psychiatry 70:185-198.
110. Hastrup H, Karlin A, and Javitch JA (2001) Symmetrical dimer of the human dopamine transporter revealed by cross-linking Cys-306 at the extracellular end of the sixth transmembrane segment. Proc Natl Acad Sci USA 98:10055-10060.
111. Haughey HM, Brown JM, Fleckenstein AE, and Hanson GR (1999) Oxygen radicals differentially affect Na+/Cl(-)-dependent transporters. Eur J Pharmacol 379: 107-110.
112. Heikkila RE, Orlansky H, and Cohen G (1975) Studies on the distinction between uptake inhibition and release of (3H)dopamine in rat brain tissue slices. Biochem Pharmacol 24:847-852.
113. Hiranita T, Kohut SJ, Soto PL, Tanda G, Kopajtic TA, and Katz JL (2014) Preclinical efficacy of N-substituted benztropine analogs as antagonists of methamphetamine self-administration in rats. J Pharmacol Exp Ther 348:174-191.
114. Hiranita T, Soto PL, Kohut SJ, Kopajtic T, Cao J, Newman AH, Tanda G, and Katz JL (2011) Decreases in cocaine self-administration with dual inhibition of the dopamine transporter and s receptors. J Pharmacol Exp Ther 339:662-677.
115. Hiranita T, Soto PL, Newman AH, and Katz JL (2009) Assessment of reinforcing effects of benztropine analogs and their effects on cocaine self-administration in rats: comparisons with monoamine uptake inhibitors. J Pharmacol Exp Ther 329:677-686.
116. Hogan KA, Staal RG, and Sonsalla PK (2000) Analysis of VMAT2 binding after methamphetamine or MPTP treatment: disparity between homogenates and vesicle preparations. J Neurochem 74:2217-2220.
117. Holton KL, Loder MK, and Melikian HE (2005) Nonclassical, distinct endocytic signals dictate constitutive and PKC-regulated neurotransmitter transporter internalization. Nat Neurosci 8:881-888.
118. Hong WC and Amara SG (2010) Membrane cholesterol modulates the outward facing conformation of the dopamine transporter and alters cocaine binding. J Biol Chem 285:32616-32626.
119. Hornykiewicz O (2006) The discovery of dopamine deficiency in the parkinsonian brain. J Neural Transm Suppl 70:9-15.
120. Howell LL and Negus SS (2014) Monoamine transporter inhibitors and substrates as treatments for stimulant abuse. Adv Pharmacol 69:129-176.
121. Huang Q, Zhou D, Chase K, Gusella JF, Aronin N, and DiFiglia M (1992) Immunohistochemical localization of the D1 dopamine receptor in rat brain reveals its axonal transport, pre- and postsynaptic localization, and prevalence in the basal ganglia, limbic system, and thalamic reticular nucleus. Proc Natl Acad Sci USA 89: 11988-11992.
122. Ingram SL, Prasad BM, and Amara SG (2002) Dopamine transporter-mediated conductances increase excitability of midbrain dopamine neurons. Nat Neurosci 5: 971-978.
123. Ishibashi K, Oda K, Ishiwata K, and Ishii K (2014) Comparison of dopamine transporter decline in a patient with Parkinson’s disease and normal aging effect. J Neurol Sci 339:207-209.
124. Jiang H, Jiang Q, and Feng J (2004) Parkin increases dopamine uptake by enhancing the cell surface expression of dopamine transporter. J Biol Chem 279:54380-54386.
125. Johanson CE, Frey KA, Lundahl LH, Keenan P, Lockhart N, Roll J, Galloway GP, Koeppe RA, Kilbourn MR, and Robbins T, et al. (2006) Cognitive function and nigrostriatal markers in abstinent methamphetamine abusers. Psychopharmacology (Berl) 185:327-338.
126. Johnson LA, Furman CA, Zhang M, Guptaroy B, and Gnegy ME (2005) Rapid delivery of the dopamine transporter to the plasmalemmal membrane upon amphetamine stimulation. Neuropharmacology 49:750-758.
127. Johnson RG, Carty SE, and Scarpa A (1981) Proton: substrate stoichiometries during active transport of biogenic amines in chromaffin ghosts. J Biol Chem 256: 5773-5780.
128. Jones SR, Gainetdinov RR, Jaber M, Giros B, Wightman RM, and Caron MG (1998) Profound neuronal plasticity in response to inactivation of the dopamine transporter. Proc Natl Acad Sci USA 95:4029-4034.
129. Jones SR, Joseph JD, Barak LS, Caron MG, and Wightman RM (1999) Dopamine neuronal transport kinetics and effects of amphetamine. J Neurochem 73: 2406-2414.
130. Kahlig KM, Binda F, Khoshbouei H, Blakely RD, McMahon DG, Javitch JA, and Galli A (2005) Amphetamine induces dopamine efflux through a dopamine transporter channel. Proc Natl Acad Sci USA 102:3495-3500.
131. Kang R, Wan J, Arstikaitis P, Takahashi H, Huang K, Bailey AO, Thompson JX, Roth AF, Drisdel RC, and Mastro R, et al. (2008) Neural palmitoyl-proteomics reveals dynamic synaptic palmitoylation. Nature 456:904-909.
132. Kantor L and Gnegy ME (1998). Protein kinase C inhibitors block amphetaminemediated dopamine release in rat striatal slices. J Pharmacol Exp Ther 284: 592-598.
133. Kessler RC, Chiu WT, Demler O, Merikangas KR, and Walters EE (2005) Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry 62:617-627.
134. Khoshbouei H, Sen N, Guptaroy B, Johnson L, Lund D, Gnegy ME, Galli A, and Javitch JA (2004) N-terminal phosphorylation of the dopamine transporter is required for amphetamine-induced efflux. PLoS Biol 2:E78.
135. Kilty JE, Lorang D, and Amara SG (1991) Cloning and expression of a cocainesensitive rat dopamine transporter. Science 254:578-579.
136. Knoth J, Isaacs JM, and Njus D (1981) Amine transport in chromaffin granule ghosts. pH dependence implies cationic form is translocated. J Biol Chem 256: 6541-6543.
137. Koob GF and Volkow ND (2010) Neurocircuitry of addiction. Neuropsychopharmacology 35:217-238.
138. Krantz DE, Peter D, Liu Y, and Edwards RH (1997) Phosphorylation of a vesicular monoamine transporter by casein kinase II. J Biol Chem 272:6752-6759.
139. Krause KH, Dresel SH, Krause J, Kung HF, and Tatsch K (2000) Increased striatal dopamine transporter in adult patients with attention deficit hyperactivity disorder: effects of methylphenidate as measured by single photon emission computed tomography. Neurosci Lett 285:107-110.
140. Kristensen AS, Andersen J, Jørgensen TN, Sørensen L, Eriksen J, Loland CJ, Strømgaard K, and Gether U (2011) SLC6 neurotransmitter transporters: structure, function, and regulation. Pharmacol Rev 63:585-640.
141. Kufahl PR and Olive MF (2011) Investigating methamphetamine craving using the extinction-reinstatement model in the rat. J Addict Res Ther S1:003.
142. Kurian MA, Li Y, Zhen J, Meyer E, Hai N, Christen HJ, Hoffmann GF, Jardine P, von Moers A, and Mordekar SR, et al. (2011) Clinical and molecular characterisation of hereditary dopamine transporter deficiency syndrome: an observational cohort and experimental study. Lancet Neurol 10:54-62.
143. Kurian MA, Zhen J, Cheng SY, Li Y, Mordekar SR, Jardine P, Morgan NV, Meyer E, Tee L, and Pasha S, et al. (2009) Homozygous loss-of-function mutations in the gene encoding the dopamine transporter are associated with infantile parkinsonism- dystonia. J Clin Invest 119:1595-1603.
144. Lee EH and Seo SR (2014) Neuroprotective roles of pituitary adenylate cyclaseactivating polypeptide in neurodegenerative diseases. BMB Rep 47:369-375.
145. Lee FJ, Liu F, Pristupa ZB, and Niznik HB (2001) Direct binding and functional coupling of alpha-synuclein to the dopamine transporters accelerate dopamineinduced apoptosis. FASEB J 15:916-926.
146. Lee FJ, Pei L, Moszczynska A, Vukusic B, Fletcher PJ, and Liu F (2007) Dopamine transporter cell surface localization facilitated by a direct interaction with the dopamine D2 receptor. EMBO J 26:2127-2136.
147. Levey AI, Hersch SM, Rye DB, Sunahara RK, Niznik HB, Kitt CA, Price DL, Maggio R, Brann MR, and Ciliax BJ (1993) Localization of D1 and D2 dopamine receptors in brain with subtype-specific antibodies. Proc Natl Acad Sci USA 90:8861-8865.
148. Levitt M, Spector S, Sjoerdsma A, and Udenfriend S (1965) Elucidation of the ratelimiting step in norepinephrine biosynthesis in the perfused guinea-pig heart. J Pharmacol Exp Ther 148:1-8.
149. Li LB, Chen N, Ramamoorthy S, Chi L, Cui XN, Wang LC, and Reith ME (2004) The role of N-glycosylation in function and surface trafficking of the human dopamine transporter. J Biol Chem 279:21012-21020.
150. Li SM, Kopajtic TA, O’Callaghan MJ, Agoston GE, Cao J, Newman AH, and Katz JL (2011) N-substituted benztropine analogs: selective dopamine transporter ligands with a fast onset of action and minimal cocaine-like behavioral effects. J Pharmacol Exp Ther 336:575-585.
151. Liang NY and Rutledge CO (1982) Comparison of the release of [3H]dopamine from isolated corpus striatum by amphetamine, fenfluramine and unlabelled dopamine. Biochem Pharmacol 31:983-992.
152. Ling W, Chang L, Hillhouse M, Ang A, Striebel J, Jenkins J, Hernandez J, Olaer M, Mooney L, and Reed S, et al. (2014) Sustained-release methylphenidate in a randomized trial of treatment of methamphetamine use disorder. Addiction 109: 1489-1500.
153. Little KY, Krolewski DM, Zhang L, and Cassin BJ (2003) Loss of striatal vesicular monoamine transporter protein (VMAT2) in human cocaine users. Am J Psychiatry 160:47-55.
154. Liu Y and Edwards RH (1997) The role of vesicular transport proteins in synaptic transmission and neural degeneration. Annu Rev Neurosci 20:125-156.
155. Loder MK and Melikian HE (2003) The dopamine transporter constitutively internalizes and recycles in a protein kinase C-regulated manner in stably transfected PC12 cell lines. J Biol Chem 278:22168-22174.
156. Loland CJ, Desai RI, Zou MF, Cao J, Grundt P, Gerstbrein K, Sitte HH, Newman AH, Katz JL, and Gether U (2008) Relationship between conformational changes in the dopamine transporter and cocaine-like subjective effects of uptake inhibitors. Mol Pharmacol 73:813-823.
157. Loland CJ, Mereu M, Okunola OM, Cao J, Prisinzano TE, Mazier S, Kopajtic T, Shi L, Katz JL, and Tanda G, et al. (2012) R-modafinil (armodafinil): a unique dopamine uptake inhibitor and potential medication for psychostimulant abuse. Biol Psychiatry 72:405-413.
158. Longo M, Wickes W, Smout M, Harrison S, Cahill S, and White JM (2010) Randomized controlled trial of dexamphetamine maintenance for the treatment of methamphetamine dependence. Addiction 105:146-154.
159. Lynch WJ, Roth ME, and Carroll ME (2002) Biological basis of sex differences in drug abuse: preclinical and clinical studies. Psychopharmacology (Berl) 164:121-137.
160. Madsen KL, Thorsen TS, Rahbek-Clemmensen T, Eriksen J, and Gether U (2012) Protein interacting with C kinase 1 (PICK1) reduces reinsertion rates of interaction partners sorted to Rab11-dependent slow recycling pathway. J Biol Chem 287:12293-12308.
161. Marek GJ, Vosmer G, and Seiden LS (1990) The effects of monoamine uptake inhibitors and methamphetamine on neostriatal 6-hydroxydopamine (6-OHDA) formation, short-term monoamine depletions and locomotor activity in the rat. Brain Res 516:1-7.
162. Mash DC, Pablo J, Ouyang Q, Hearn WL, and Izenwasser S (2002) Dopamine transport function is elevated in cocaine users. J Neurochem 81:292-300.
163. Mayfield RD and Zahniser NR (2001) Dopamine D2 receptor regulation of the dopamine transporter expressed in Xenopus laevis oocytes is voltage-independent. Mol Pharmacol 59:113-121.
164. Mazei-Robison MS, Couch RS, Shelton RC, Stein MA, and Blakely RD (2005) Sequence variation in the human dopamine transporter gene in children with attention deficit hyperactivity disorder. Neuropharmacology 49:724-736.
165. McCann UD, Wong DF, Yokoi F, Villemagne V, Dannals RF, and Ricaurte GA (1998) Reduced striatal dopamine transporter density in abstinent methamphetamine and methcathinone users: evidence from positron emission tomography studies with [11C]WIN-35,428. J Neurosci 18:8417-8422.
166. McElroy SL, Kotwal R, Malhotra S, Nelson EB, Keck PE, and Nemeroff CB (2004) Are mood disorders and obesity related? A review for the mental health professional. J Clin Psychiatry 65:634-651, quiz 730.
167. McGuire BA, Baladi MG, and France CP (2011) Eating high-fat chow enhances sensitization to the effects of methamphetamine on locomotion in rats. Eur J Pharmacol 658:156-159.
168. Meiergerd SM, Patterson TA, and Schenk JO (1993) D2 receptors may modulate the function of the striatal transporter for dopamine: kinetic evidence from studies in vitro and in vivo. J Neurochem 61:764-767.
169. Melikian HE and Buckley KM (1999) Membrane trafficking regulates the activity of the human dopamine transporter. J Neurosci 19:7699-7710.
170. Mergy MA, Gowrishankar R, Gresch PJ, Gantz SC, Williams J, Davis GL, Wheeler CA, Stanwood GD, Hahn MK, and Blakely RD (2014) The rare DAT coding variant Val559 perturbs DA neuron function, changes behavior, and alters in vivo responses to psychostimulants. Proc Natl Acad Sci USA 111:E4779-E4788.
171. Merikangas KR, He JP, Burstein M, Swanson SA, Avenevoli S, Cui L, Benjet C, Georgiades K, and Swendsen J (2010) Lifetime prevalence of mental disorders in U.S. adolescents: results from the National Comorbidity Survey Replication-Adolescent Supplement (NCS-A). J Am Acad Child Adolesc Psychiatry 49:980-989.
172. Metzger RR, Haughey HM, Wilkins DG, Gibb JW, Hanson GR, and Fleckenstein AE (2000) Methamphetamine-induced rapid decrease in dopamine transporter function: role of dopamine and hyperthermia. J Pharmacol Exp Ther 295:1077-1085.
173. Miller GW, Gainetdinov RR, Levey AI, and Caron MG (1999) Dopamine transporters and neuronal injury. Trends Pharmacol Sci 20:424-429.
174. Milner HE, Béliveau R, and Jarvis SM (1994) The in situ size of the dopamine transporter is a tetramer as estimated by radiation inactivation. Biochim Biophys Acta 1190:185-187.
175. Miranda M, Dionne KR, Sorkina T, and Sorkin A (2007) Three ubiquitin conjugation sites in the amino terminus of the dopamine transporter mediate protein kinase C-dependent endocytosis of the transporter. Mol Biol Cell 18:313-323.
176. Miranda M, Wu CC, Sorkina T, Korstjens DR, and Sorkin A (2005) Enhanced ubiquitylation and accelerated degradation of the dopamine transporter mediated by protein kinase C. J Biol Chem 280:35617-35624.
177. Mooney ME, Herin DV, Schmitz JM, Moukaddam N, Green CE, and Grabowski J (2009) Effects of oral methamphetamine on cocaine use: a randomized, doubleblind, placebo-controlled trial. Drug Alcohol Depend 101:34-41.
178. Moszczynska A, Saleh J, Zhang H, Vukusic B, Lee FJ, and Liu F (2007) Parkin disrupts the alpha-synuclein/dopamine transporter interaction: consequences toward dopamine-induced toxicity. J Mol Neurosci 32:217-227.
179. Mukherjee S, Decina P, Bocola V, Saraceni F, and Scapicchio PL (1996) Diabetes mellitus in schizophrenic patients. Compr Psychiatry 37:68-73.
180. Nakamura K, Sekine Y, Ouchi Y, Tsujii M, Yoshikawa E, Futatsubashi M, Tsuchiya KJ, Sugihara G, Iwata Y, and Suzuki K, et al. (2010) Brain serotonin and dopamine transporter bindings in adults with high-functioning autism. Arch Gen Psychiatry 67:59-68.
181. Narendran R, Lopresti BJ, Martinez D, Mason NS, Himes M, May MA, Daley DC, Price JC, Mathis CA, and Frankle WG (2012) In vivo evidence for low striatal vesicular monoamine transporter 2 (VMAT2) availability in cocaine abusers. Am J Psychiatry 169:55-63.
182. Nestler EJ and Carlezon WA Jr (2006) The mesolimbic dopamine reward circuit in depression. Biol Psychiatry 59:1151-1159.
183. Ng J, Zhen J, Meyer E, Erreger K, Li Y, Kakar N, Ahmad J, Thiele H, Kubisch C, and Rider NL, et al. (2014) Dopamine transporter deficiency syndrome: phenotypic spectrum from infancy to adulthood. Brain 137: 1107-1119.
184. Nguyen M, Roth A, Kyzar EJ, Poudel MK, Wong K, Stewart AM, and Kalueff AV (2014) Decoding the contribution of dopaminergic genes and pathways to autism spectrum disorder (ASD). Neurochem Int 66:15-26.
185. Nickell JR, Siripurapu KB, Vartak A, Crooks PA, and Dwoskin LP (2014) The vesicular monoamine transporter-2: an important pharmacological target for the discovery of novel therapeutics to treat methamphetamine abuse. Adv Pharmacol 69:71-106.
186. Nicolaysen LC and Justice JB Jr (1988) Effects of cocaine on release and uptake of dopamine in vivo: differentiation by mathematical modeling. Pharmacol Biochem Behav 31:327-335.
187. Nirenberg MJ, Chan J, Liu Y, Edwards RH, and Pickel VM (1996a) Ultrastructural localization of the vesicular monoamine transporter-2 in midbrain dopaminergic neurons: potential sites for somatodendritic storage and release of dopamine. J Neurosci 16:4135-4145.
188. Nirenberg MJ, Chan J, Liu Y, Edwards RH, and Pickel VM (1997a) Vesicular monoamine transporter-2: immunogold localization in striatal axons and terminals. Synapse 26:194-198.
189. Nirenberg MJ, Chan J, Vaughan RA, Uhl GR, Kuhar MJ, and Pickel VM (1997b) Immunogold localization of the dopamine transporter: an ultrastructural study of the rat ventral tegmental area. J Neurosci 17:4037-4044.
190. Nirenberg MJ, Liu Y, Peter D, Edwards RH, and Pickel VM (1995) The vesicular monoamine transporter 2 is present in small synaptic vesicles and preferentially localizes to large dense core vesicles in rat solitary tract nuclei. Proc Natl Acad Sci USA 92:8773-8777.
191. Nirenberg MJ, Vaughan RA, Uhl GR, Kuhar MJ, and Pickel VM (1996b) The dopamine transporter is localized to dendritic and axonal plasma membranes of nigrostriatal dopaminergic neurons. J Neurosci 16:436-447.
192. Niswender KD, Daws LC, Avison MJ, and Galli A (2011) Insulin regulation of monoamine signaling: pathway to obesity. Neuropsychopharmacology 36: 359-360.
193. Omiatek DM, Bressler AJ, Cans AS, Andrews AM, Heien ML, and Ewing AG (2013) The real catecholamine content of secretory vesicles in the CNS revealed by electrochemical cytometry. Sci Rep 3:1447.
194. Onoa B, Li H, Gagnon-Bartsch JA, Elias LA, and Edwards RH (2010) Vesicular monoamine and glutamate transporters select distinct synaptic vesicle recycling pathways. J Neurosci 30:7917-7927.
195. Owens WA, Sevak RJ, Galici R, Chang X, Javors MA, Galli A, France CP, and Daws LC (2005) Deficits in dopamine clearance and locomotion in hypoinsulinemic rats unmask novel modulation of dopamine transporters by amphetamine. J Neurochem 94:1402-1410.
196. Patel AP, Cerruti C, Vaughan RA, and Kuhar MJ (1994) Developmentally regulated glycosylation of dopamine transporter. Brain Res Dev Brain Res 83:53-58.
197. Patterson TA, Brot MD, Zavosh A, Schenk JO, Szot P, and Figlewicz DP (1998) Food deprivation decreases mRNA and activity of the rat dopamine transporter. Neuroendocrinology 68:11-20.
198. Penmatsa A, Wang KH, and Gouaux E (2013) X-ray structure of dopamine transporter elucidates antidepressant mechanism. Nature 503:85-90.
199. Peter D, Jimenez J, Liu Y, Kim J, and Edwards RH (1994) The chromaffin granule and synaptic vesicle amine transporters differ in substrate recognition and sensitivity to inhibitors. J Biol Chem 269:7231-7237.
200. Pifl C, Rajput A, Reither H, Blesa J, Cavada C, Obeso JA, Rajput AH, and Hornykiewicz O (2014) Is Parkinson’s disease a vesicular dopamine storage disorder? Evidence from a study in isolated synaptic vesicles of human and nonhuman primate striatum. J Neurosci 34:8210-8218.
201. Pletscher A (1977) Effect of neuroleptics and other drugs on monoamine uptake by membranes of adrenal chromaffin granules. Br J Pharmacol 59:419-424.
202. Polymeropoulos MH, Lavedan C, Leroy E, Ide SE, Dehejia A, Dutra A, Pike B, Root H, Rubenstein J, and Boyer R, et al. (1997) Mutation in the alpha-synuclein gene identified in families with Parkinson’s disease. Science 276:2045-2047.
203. Pothos EN, Larsen KE, Krantz DE, Liu Y, Haycock JW, Setlik W, Gershon MD, Edwards RH, and Sulzer D (2000) Synaptic vesicle transporter expression regulates vesicle phenotype and quantal size. J Neurosci 20:7297-7306.
204. Pramod AB, Foster J, Carvelli L, and Henry LK (2013) SLC6 transporters: structure, function, regulation, disease association and therapeutics. Mol Aspects Med 34: 197-219.
205. Rao A, Simmons D, and Sorkin A (2011) Differential subcellular distribution of endosomal compartments and the dopamine transporter in dopaminergic neurons. Mol Cell Neurosci 46:148-158.
206. Reith ME, Berfield JL, Wang LC, Ferrer JV, and Javitch JA (2001) The uptake inhibitors cocaine and benztropine differentially alter the conformation of the human dopamine transporter. J Biol Chem 276:29012-29018.
207. Reith ME, Blough BE, Hong WC, Jones KT, Schmitt KC, Baumann MH, Partilla JS, Rothman RB, and Katz JL (2015) Behavioral, biological, and chemical perspectives on atypical agents targeting the dopamine transporter. Drug Alcohol Depend 147: 1-19.
208. Reith ME and Coffey LL (1994) Structure-activity relationships for cocaine congeners in inhibiting dopamine uptake into rat brain synaptic vesicles and bovine chromaffin granule ghosts. J Pharmacol Exp Ther 271:1444-1452.
209. Requena DF, Parra LA, Baust TB, Quiroz M, Leak RK, Garcia-Olivares J, and Torres GE (2009) The molecular chaperone Hsc70 interacts with the vesicular monoamine transporter-2. J Neurochem 110:581-594.
210. Rice ME and Cragg SJ (2008) Dopamine spillover after quantal release: rethinking dopamine transmission in the nigrostriatal pathway. Brain Res Brain Res Rev 58: 303-313.
211. Richards TL and Zahniser NR (2009) Rapid substrate-induced down-regulation in function and surface localization of dopamine transporters: rat dorsal striatum versus nucleus accumbens. J Neurochem 108:1575-1584.
212. Richelson E, Boules M, and Fredrickson P (2003) Neurotensin agonists: possible drugs for treatment of psychostimulant abuse. Life Sci 73:679-690.
213. Rickhag M, Hansen FH, Sørensen G, Strandfelt KN, Andresen B, Gotfryd K, Madsen KL, Vestergaard-Klewe I, Ammendrup-Johnsen I, and Eriksen J, et al. (2013a) A C-terminal PDZ domain-binding sequence is required for striatal distribution of the dopamine transporter. Nat Commun 4:1580.
214. Rickhag M, Owens WA, Winkler MT, Strandfelt KN, Rathje M, Sørensen G, Andresen B, Madsen KL, Jørgensen TN, and Wörtwein G, et al. (2013b) Membrane-permeable C-terminal dopamine transporter peptides attenuate amphetamine-evoked dopamine release. J Biol Chem 288:27534-27544.
215. Riddle EL, Fleckenstein AE, and Hanson GR (2005) Role of monoamine transporters in mediating psychostimulant effects. AAPS J 7:E847-E851.
216. Riddle EL, Topham MK, Haycock JW, Hanson GR, and Fleckenstein AE (2002) Differential trafficking of the vesicular monoamine transporter-2 by methamphetamine and cocaine. Eur J Pharmacol 449:71-74.
217. Rilstone JJ, Alkhater RA, and Minassian BA (2013) Brain dopamine-serotonin vesicular transport disease and its treatment. N Engl J Med 368:543-550.
218. Ritz MC, Lamb RJ, Goldberg SR, and Kuhar MJ (1987) Cocaine receptors on dopamine transporters are related to self-administration of cocaine. Science 237: 1219-1223.
219. Rothman RB, Partilla JS, Baumann MH, Lightfoot-Siordia C, and Blough BE (2012) Studies of the biogenic amine transporters. 14. Identification of low-efficacy “partial” substrates for the biogenic amine transporters. J Pharmacol Exp Ther 341: 251-262.
220. Rubia K, Halari R, Cubillo A, Mohammad AM, Brammer M, and Taylor E (2009) Methylphenidate normalises activation and functional connectivity deficits in attention and motivation networks in medication-naïve children with ADHD during a rewarded continuous performance task. Neuropharmacology 57:640-652.
221. Sakrikar D, Mazei-Robison MS, Mergy MA, Richtand NW, Han Q, Hamilton PJ, Bowton E, Galli A, Veenstra-Vanderweele J, and Gill M, et al. (2012) Attention deficit/hyperactivity disorder-derived coding variation in the dopamine transporter disrupts microdomain targeting and trafficking regulation. J Neurosci 32: 5385-5397.
222. Sandoval V, Riddle EL, Hanson GR, and Fleckenstein AE (2002) Methylphenidate redistributes vesicular monoamine transporter-2: role of dopamine receptors. J Neurosci 22:8705-8710.
223. Sandoval V, Riddle EL, Hanson GR, and Fleckenstein AE (2003) Methylphenidate alters vesicular monoamine transport and prevents methamphetamine-induced dopaminergic deficits. J Pharmacol Exp Ther 304:1181-1187.
224. Sandoval V, Riddle EL, Ugarte YV, Hanson GR, and Fleckenstein AE (2001). Methamphetamine-induced rapid and reversible changes in dopamine transporter function: an in vitro model. J Neurosci 21:1413-1419.
225. Saunders C, Ferrer JV, Shi L, Chen J, Merrill G, Lamb ME, Leeb-Lundberg LM, Carvelli L, Javitch JA, and Galli A (2000) Amphetamine-induced loss of human dopamine transporter activity: an internalization-dependent and cocaine-sensitive mechanism. Proc Natl Acad Sci USA 97:6850-6855.
226. Schmitt KC and Reith ME (2011) The atypical stimulant and nootropic modafinil interacts with the dopamine transporter in a different manner than classical cocaine-like inhibitors. PLoS One 6:e25790.
227. Schmitt KC, Rothman RB, and Reith ME (2013) Nonclassical pharmacology of the dopamine transporter: atypical inhibitors, allosteric modulators, and partial substrates. J Pharmacol Exp Ther 346:2-10.
228. Schubiner H, Saules KK, Arfken CL, Johanson CE, Schuster CR, Lockhart N, Edwards A, Donlin J, and Pihlgren E (2002) Double-blind placebo-controlled trial of methylphenidate in the treatment of adult ADHD patients with comorbid cocaine dependence. Exp Clin Psychopharmacol 10:286-294.
229. Seeman P and Niznik HB (1990) Dopamine receptors and transporters in Parkinson’s disease and schizophrenia. FASEB J 4:2737-2744.
230. Sevak RJ, Koek W, Owens WA, Galli A, Daws LC, and France CP (2008) Feeding conditions differentially affect the neurochemical and behavioral effects of dopaminergic drugs in male rats. Eur J Pharmacol 592:109-115.
231. Shan J, Javitch JA, Shi L, and Weinstein H (2011) The substrate-driven transition to an inward-facing conformation in the functional mechanism of the dopamine transporter. PLoS One 6:e16350.
232. Shimada S, Kitayama S, Lin CL, Patel A, Nanthakumar E, Gregor P, Kuhar M, and Uhl G (1991) Cloning and expression of a cocaine-sensitive dopamine transporter complementary DNA. Science 254:576-578.
233. Simon GE, Von Korff M, Saunders K, Miglioretti DL, Crane PK, van Belle G, and Kessler RC (2006) Association between obesity and psychiatric disorders in the US adult population. Arch Gen Psychiatry 63:824-830.
234. Snyder SH, Glowinski J, and Axelrod J (1965) The Storage of Norepinephrine and Some of Its Derivatives in Brain Synaptosomes. Life Sci 4:797-807.
235. Søgaard U, Michalow J, Butler B, Lund Laursen A, Ingersen SH, Skrumsager BK, and Rafaelsen OJ (1990) A tolerance study of single and multiple dosing of the selective dopamine uptake inhibitor GBR 12909 in healthy subjects. Int Clin Psychopharmacol 5:237-251.
236. Sonders MS, Zhu SJ, Zahniser NR, Kavanaugh MP, and Amara SG (1997) Multiple ionic conductances of the human dopamine transporter: the actions of dopamine and psychostimulants. J Neurosci 17:960-974.
237. Sorkina T, Doolen S, Galperin E, Zahniser NR, and Sorkin A (2003) Oligomerization of dopamine transporters visualized in living cells by fluorescence resonance energy transfer microscopy. J Biol Chem 278:28274-28283.
238. Sorkina T, Hoover BR, Zahniser NR, and Sorkin A (2005) Constitutive and protein kinase C-induced internalization of the dopamine transporter is mediated by a clathrin-dependent mechanism. Traffic 6:157-170.
239. Sorkina T, Miranda M, Dionne KR, Hoover BR, Zahniser NR, and Sorkin A (2006) RNA interference screen reveals an essential role of Nedd4-2 in dopamine transporter ubiquitination and endocytosis. J Neurosci 26:8195-8205.
240. Spatola M and Wider C (2014) Genetics of Parkinson’s disease: the yield. Parkinsonism Relat Disord 20 (Suppl 1):S35-S38.
241. Sulzer D (2011) How addictive drugs disrupt presynaptic dopamine neurotransmission. Neuron 69:628-649.
242. Sulzer D, Maidment NT, and Rayport S (1993) Amphetamine and other weak bases act to promote reverse transport of dopamine in ventral midbrain neurons. J Neurochem 60:527-535.
243. Sulzer D, Sonders MS, Poulsen NW, and Galli A (2005) Mechanisms of neurotransmitter release by amphetamines: a review. Prog Neurobiol 75:406-433.
244. Suzuki M, Desmond TJ, Albin RL, and Frey KA (2001) Vesicular neurotransmitter transporters in Huntington’s disease: initial observations and comparison with traditional synaptic markers. Synapse 41:329-336.
245. Swanson JM, Kinsbourne M, Nigg J, Lanphear B, Stefanatos GA, Volkow N, Taylor E, Casey BJ, Castellanos FX, and Wadhwa PD (2007) Etiologic subtypes of attention-deficit/hyperactivity disorder: brain imaging, molecular genetic and environmental factors and the dopamine hypothesis. Neuropsychol Rev 17:39-59.
246. Takahashi N and Uhl G (1997) Murine vesicular monoamine transporter 2: molecular cloning and genomic structure. Brain Res Mol Brain Res 49:7-14.
247. Tanda G, Newman AH, Ebbs AL, Tronci V, Green JL, Tallarida RJ, and Katz JL (2009a) Combinations of cocaine with other dopamine uptake inhibitors: assessment of additivity. J Pharmacol Exp Ther 330:802-809.
248. Tanda G, Newman AH, and Katz JL (2009b) Discovery of drugs to treat cocaine dependence: behavioral and neurochemical effects of atypical dopamine transport inhibitors. Adv Pharmacol 57:253-289.
249. Taylor FB and Russo J (2000) Efficacy of modafinil compared to dextroamphetamine for the treatment of attention deficit hyperactivity disorder in adults. J Child Adolesc Psychopharmacol 10:311-320.
250. Tiihonen J, Kuoppasalmi K, Föhr J, Tuomola P, Kuikanmäki O, Vorma H, Sokero P, Haukka J, and Meririnne E (2007) A comparison of aripiprazole, methylphenidate, and placebo for amphetamine dependence. Am J Psychiatry 164:160-162.
251. Torres B and Ruoho AE (2014) N-terminus regulation of VMAT2 mediates methamphetamine-stimulated efflux. Neuroscience 259:194-202.
252. Torres GE, Carneiro A, Seamans K, Fiorentini C, Sweeney A, Yao WD, and Caron MG (2003) Oligomerization and trafficking of the human dopamine transporter. Mutational analysis identifies critical domains important for the functional expression of the transporter. J Biol Chem 278:2731-2739.
253. Torres GE, Yao WD, Mohn AR, Quan H, Kim KM, Levey AI, Staudinger J, and Caron MG (2001) Functional interaction between monoamine plasma membrane transporters and the synaptic PDZ domain-containing protein PICK1. Neuron 30:121-134.
254. Truong JG, Newman AH, Hanson GR, and Fleckenstein AE (2004) Dopamine D2 receptor activation increases vesicular dopamine uptake and redistributes vesicular monoamine transporter-2 protein. Eur J Pharmacol 504:27-32.
255. Truong JG, Rau KS, Hanson GR, and Fleckenstein AE (2003) Pramipexole increases vesicular dopamine uptake: implications for treatment of Parkinson’s neurodegeneration. Eur J Pharmacol 474:223-226.
256. Turner D (2006) A review of the use of modafinil for attention-deficit hyperactivity disorder. Expert Rev Neurother 6:455-468.
257. Vaughan RA and Foster JD (2013) Mechanisms of dopamine transporter regulation in normal and disease states. Trends Pharmacol Sci 34:489-496.
258. Vaughan RA, Huff RA, Uhl GR, and Kuhar MJ (1997) Protein kinase C-mediated phosphorylation and functional regulation of dopamine transporters in striatal synaptosomes. J Biol Chem 272:15541-15546.
259. Vaughan RA and Kuhar MJ (1996) Dopamine transporter ligand binding domains. Structural and functional properties revealed by limited proteolysis. J Biol Chem 271:21672-21680.
260. Velázquez-Sánchez C, García-Verdugo JM, Murga J, and Canales JJ (2013) The atypical dopamine transport inhibitor, JHW 007, prevents amphetamine-induced sensitization and synaptic reorganization within the nucleus accumbens. Prog Neuropsychopharmacol Biol Psychiatry 44:73-80.
261. Volkow ND, Chang L, Wang GJ, Fowler JS, Leonido-Yee M, Franceschi D, Sedler MJ, Gatley SJ, Hitzemann R, and Ding YS, et al. (2001) Association of dopamine transporter reduction with psychomotor impairment in methamphetamine abusers. Am J Psychiatry 158:377-382.
262. Volkow ND, Wang GJ, Kollins SH, Wigal TL, Newcorn JH, Telang F, Fowler JS, Zhu W, Logan J, and Ma Y, et al. (2009) Evaluating dopamine reward pathway in ADHD: clinical implications. JAMA 302:1084-1091.
263. Volkow ND, Wang GJ, Newcorn J, Fowler JS, Telang F, Solanto MV, Logan J, Wong C, Ma Y, and Swanson JM, et al. (2007a) Brain dopamine transporter levels in treatment and drug naïve adults with ADHD. Neuroimage 34:1182-1190.
264. Volkow ND, Wang GJ, Newcorn J, Telang F, Solanto MV, Fowler JS, Logan J, Ma Y, Schulz K, and Pradhan K, et al. (2007b) Depressed dopamine activity in caudate and preliminary evidence of limbic involvement in adults with attention-deficit/hyperactivity disorder. Arch Gen Psychiatry 64:932-940.
265. Volz TJ, Farnsworth SJ, King JL, Riddle EL, Hanson GR, and Fleckenstein AE (2007) Methylphenidate administration alters vesicular monoamine transporter-2 function in cytoplasmic and membrane-associated vesicles. J Pharmacol Exp Ther 323:738-745.
266. Volz TJ and Schenk JO (2004) L-arginine increases dopamine transporter activity in rat striatum via a nitric oxide synthase-dependent mechanism. Synapse 54: 173-182.
267. Vosburg SK, Hart CL, Haney M, Rubin E, and Foltin RW (2010) Modafinil does not serve as a reinforcer in cocaine abusers. Drug Alcohol Depend 106:233-236.
268. Waites CL, Mehta A, Tan PK, Thomas G, Edwards RH, and Krantz DE (2001) An acidic motif retains vesicular monoamine transporter 2 on large dense core vesicles. J Cell Biol 152:1159-1168.
269. Watson CS, Alyea RA, Hawkins BE, Thomas ML, Cunningham KA, and Jakubas AA (2006) Estradiol effects on the dopamine transporter - protein levels, subcellular location, and function. J Mol Signal 1:5.
270. Watson CS and Gametchu B (1999) Membrane-initiated steroid actions and the proteins that mediate them. Proc Soc Exp Biol Med 220:9-19.
271. Weyandt LL, Oster DR, Marraccini ME, Gudmundsdottir BG, Munro BA, Zavras BM, and Kuhar B (2014) Pharmacological interventions for adolescents and adults with ADHD: stimulant and nonstimulant medications and misuse of prescription stimulants. Psychol Res Behav Manag 7:223-249.
272. Wheeler DD, Edwards AM, Chapman BM, and Ondo JG (1993) A model of the sodium dependence of dopamine uptake in rat striatal synaptosomes. Neurochem Res 18: 927-936.
273. Wiederman MW and Pryor T (1996) Substance use among women with eating disorders. Int J Eat Disord 20:163-168.
274. Wigal SB, Chae S, Patel A, and Steinberg-Epstein R (2010) Advances in the treatment of attention-deficit/hyperactivity disorder: a guide for pediatric neurologists. Semin Pediatr Neurol 17:230-236.
275. Williams JM, Owens WA, Turner GH, Saunders C, Dipace C, Blakely RD, France CP, Gore JC, Daws LC, and Avison MJ, et al. (2007) Hypoinsulinemia regulates amphetamine-induced reverse transport of dopamine. PLoS Biol 5: e274.
276. Wilson JM, Levey AI, Bergeron C, Kalasinsky K, Ang L, Peretti F, Adams VI, Smialek J, Anderson WR, and Shannak K, et al. (1996) Striatal dopamine, dopamine transporter, and vesicular monoamine transporter in chronic cocaine users. Ann Neurol 40:428-439.
277. Yahyavi-Firouz-Abadi N and See RE (2009) Anti-relapse medications: preclinical models for drug addiction treatment. Pharmacol Ther 124:235-247.
278. Yao J and Hersh LB (2007) The vesicular monoamine transporter 2 contains trafficking signals in both its N-glycosylation and C-terminal domains. J Neurochem 100:1387-1396.
279. Zapata A and Shippenberg TS (2002) D(3) receptor ligands modulate extracellular dopamine clearance in the nucleus accumbens. J Neurochem 81:1035-1042.
280. Zhen J, Antonio T, Cheng SY, Ali S, Jones KT, and Reith ME (2015) Dopamine transporter oligomerization: impact of combining protomers with differential cocaine analog binding affinities. J Neurochem 133:167-173.
281. Zhou Z, Zhen J, Karpowich NK, Goetz RM, Law CJ, Reith ME, and Wang DN (2007) LeuT-desipramine structure reveals how antidepressants block neurotransmitter reuptake. Science 317:1390-1393.
282. Zhu SJ, Kavanaugh MP, Sonders MS, Amara SG, and Zahniser NR (1997) Activation of protein kinase C inhibits uptake, currents and binding associated with the human dopamine transporter expressed in Xenopus oocytes. J Pharmacol Exp Ther 282:1358-1365.
283. Zubieta JK, Huguelet P, Ohl LE, Koeppe RA, Kilbourn MR, Carr JM, Giordani BJ, and Frey KA (2000) High vesicular monoamine transporter binding in asymptomatic bipolar I disorder: sex differences and cognitive correlates. Am J Psychiatry 157:1619-1628.
284. Zubieta JK, Taylor SF, Huguelet P, Koeppe RA, Kilbourn MR, and Frey KA (2001) Vesicular monoamine transporter concentrations in bipolar disorder type I, schizophrenia, and healthy subjects. Biol Psychiatry 49:110-116.